GSK suspends trial of drug formulated from red wine substance

05/5/2010 | Wall Street Journal, The

GlaxoSmithKline stopped a clinical trial of SRT501, a compound derived from the red wine substance resveratrol, in multiple myeloma patients after some of them developed cast nephropathy. GSK, which is developing the drug with Sirtris Pharmaceuticals, said its decision comes "out of an abundance of caution" as it reviews clinical data further.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC